Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients
BackgroundClone-directed therapy is essential for managing monoclonal gammopathy of renal significance (MGRS), as it reduces the nephrotoxic monoclonal protein burden and preserves renal function. However, due to the rarity and frequent misdiagnosis of MGRS, there is no evidence-based standard first...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2026-06-01
|
| Serie: | Frontiers in Immunology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1722204/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|